Objective To explore the therapeutic effect of Degludec insulin Liraglutide on obese type 2 diabetes mellitus(T2DM)with poor treatment effect of Metformin.Methods A total of 95 obese T2DM patients with inadequate glycemic control after Metformin therapy admitted to the Second Affiliated Hospital of Guilin Medical University from July 2022 to February 2024 were enrolled.Using a randomized digital table method,patients were divided into observation group(n=47)and control group(n=48).The patients of observation group received Degludec insulin Liraglutide,while the patients of control group was treated with Glargine insulin.Body mass index(BMI),serum C-peptide levels,blood glucose parameters,pancreatic function,lipid profiles,and adverse reaction incidence were compared between two groups.Results After treatment,BMI,postprandial 2-hour blood glucose,fasting blood glucose,glycated hemoglobin,total cholesterol,and low-density lipoprotein cholesterol were significantly lower in observation group than those in control group(P＜0.05).Pancreatic β-cell function index,insulin resistance index,postprandial 2-hour C-peptide,fasting C-peptide,and high-density lipoprotein cholesterol were significantly higher in observation group than those in control group(P＜0.05).There were fewer adverse reactions in observation group than those in control group(P＜0.05).Conclusion The use of Degludec insulin Liraglutide in the treatment of obese T2DM patients with poor effect of Metformin can achieve satisfactory results during the treatment,and pancreatic function,blood glucose,blood lipid and BMI have been significantly improved.The clinical application has a high safety.

Objective To explore the therapeutic effect of Degludec insulin Liraglutide on obese type 2 diabetes mellitus(T2DM)with poor treatment effect of Metformin.Methods A total of 95 obese T2DM patients with inadequate glycemic control after Metformin therapy admitted to the Second Affiliated Hospital of Guilin Medical University from July 2022 to February 2024 were enrolled.Using a randomized digital table method,patients were divided into observation group(n=47)and control group(n=48).The patients of observation group received Degludec insulin Liraglutide,while the patients of control group was treated with Glargine insulin.Body mass index(BMI),serum C-peptide levels,blood glucose parameters,pancreatic function,lipid profiles,and adverse reaction incidence were compared between two groups.Results After treatment,BMI,postprandial 2-hour blood glucose,fasting blood glucose,glycated hemoglobin,total cholesterol,and low-density lipoprotein cholesterol were significantly lower in observation group than those in control group(P＜0.05).Pancreatic β-cell function index,insulin resistance index,postprandial 2-hour C-peptide,fasting C-peptide,and high-density lipoprotein cholesterol were significantly higher in observation group than those in control group(P＜0.05).There were fewer adverse reactions in observation group than those in control group(P＜0.05).Conclusion The use of Degludec insulin Liraglutide in the treatment of obese T2DM patients with poor effect of Metformin can achieve satisfactory results during the treatment,and pancreatic function,blood glucose,blood lipid and BMI have been significantly improved.The clinical application has a high safety.

Preclinical studies have shown that metformin, an activator of AMP-activated protein kinase (AMPK) , can inhibit the growth of lymphoma cells without affecting the function of normal lymphocytes, promote the apoptosis of lymphoma cells and improve the tumor immune environment. Clinical studies have shown that metformin can improve the efficacy of chemotherapy and prognosis of non-Hodgkin lymphoma (NHL) . Through the influence on glucose metabolism, it can improve blood glucose level and reduce the incidence of steroid diabetes. The main molecular mechanisms of metformin against NHL include activating AMPK in tumor cells, inhibiting mammalian target of rapamycin signal, inhibiting key cholesterol synthesis, improving glucose metabolism, enhancing highly cytotoxic T lymphocyte (CTL) activity and so on. Current research shows that metformin may become a new strategy for the treatment of NHL.